Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

May 28, 2028

Study Completion Date

May 28, 2028

Conditions
Primary Hyperaldosteronism Due to Adrenal Adenoma
Interventions
PROCEDURE

Unilateral adrenalectomy

Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.

DRUG

Medical treatment (eplerenone)

The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.

Trial Locations (3)

41345

RECRUITING

University of Gothenburg, Gothenburg

Unknown

NOT_YET_RECRUITING

Karolinska University Hospital, Stockholm, Sweden., Stockholm

NOT_YET_RECRUITING

Umeå University, Umeå, Sweden., Umeå

All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

collaborator

Umeå University

OTHER

lead

Göteborg University

OTHER